Ta'lim fidoyilariAnnotatsiya
Maqolada empagliflozinning surunkali yurak yetishmovchiligi (SYE) va surunkali buyrak kasalligi (SBK) bo‘lgan bemorlarda yog‘ to‘qimasiga ta’siri o‘rganilgan. 6 oylik davolashdan so‘ng bioimpedansometriya umumiy, visseral va teri osti yog‘ massasi sezilarli darajada kamayganini, kardiometabolik ko‘rsatkichlarning yaxshilanganini va buyrak filtrlash tezligiga (SKF) sezilarli ta’sir ko‘rsatmaganini ko‘rsatdi. Empagliflozin istiqbolli dori sifatida ko‘rib chiqilib, qo‘shimcha tadqiqotlarni talab qiladi.
Kalit so'zlar:
surunkali yurak yetishmovchiligi, surunkali buyrak kasalligi, empagliflozin, bioimpedansometriya, visseral yog‘, kardiometabolik xavf.
Foydalanilgan adabiyotlar
1. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Ruilope LM, et al. Cardiovascular and kidney outcomes with finerenone in patients with CKD and type 2
diabetes:
TA’LIM FIDOYILARI
FIDELIO-DKD trial. Kidney Int. 2019;96(2):469-481.
doi:10.1016/j.kint.2019.11.028.
2. Bakris G.L. et al. (2021). Finerenone in Patients with Chronic Kidney Disease and
Type 2 Diabetes. New England Journal of Medicine, 383, pp. 2219-2229.
3. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of
finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med.
2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956.
4. Bhatt D.L. et al. (2021). Sotagliflozin Reduces Heart Failure Events in Patients with
Diabetes and CKD Regardless of Albuminuria Status. Journal of the American
College of Cardiology, 78(1), pp. 101-110.
5. Cooper M.E. et al. (2021). The Interplay between Diabetes, Heart Failure, and
Chronic Kidney Disease: Mechanisms and Therapeutic Implications. Diabetologia,
64(2), pp. 271-281.
6. Eckardt, K. U., et al. “The Importance of Nephrologist-Cardiologist Collaboration in
Managing Patients with Cardiorenal Syndrome.” Kidney International, vol. 99, no. 2,
2021, pp. 276-288.
7. Filippatos G., Anker S.D., Böhm M. et al. (2022). Benefits of Finerenone to Improve
Outcomes in Patients With Kidney Disease Diabetes. Journal of the American
College of Cardiology, 79(12), pp. 1508-1518.
8. Heerspink H.J.L. et al. (2021). Rationale and Design of the EMPA-KIDNEY Study.
Clinical Journal of the American Society of Nephrology, 16(1), pp. 124-136.
9. Jardine M.J. et al. (2021). The Role of Finerenone in Cardiorenal Protection. Lancet
Diabetes & Endocrinology, 9(7), pp. 649-659.
10. Kemp C.D., Conte J.V. (2021). The Pathophysiology of Heart Failure.
Cardiovascular Pathology, 30(2), pp. 79-89.
